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Introduction
Adrenal suppression with high doses of inhaled corticos-
teroids has been reported in the literature with sugges-
tion of fluticasone propionate (FP) being a more potent
adrenal suppressant than budesonide (BUD). To our
knowledge, we present the first case of adrenal suppres-
sion after change from high dose FP to BUD therapy.
Case description
A ten-year-old boy with asthma, peanut allergy, and
allergic rhinitis had been maintained on a regimen of
FP/salmeterol 500 mcg per day and mometasone furoate
nasal spray 50 mcg per day. During exacerbations FP
500 mcg per day was added. He had no oral steroid
usage. After a stable period with only FP/salmeterol, his
regimen was changed to BUD/formoterol 800 mcg per
day. Shortly after this change in regimen, he began to
experience spells of dizziness, fatigue, nausea and dia-
phoresis with exercise. A random glucose was low at 3.4
mol/L and an AM cortisol was low at 67 nmol/L. With
endocrinologist recommendation adrenal suppression
was diagnosed, hydrocortisone therapy at 18 mg/m
2 and
ciclesonide were initiated. He is currently stable, taper-
ing hydrocortisone therapy, with plans for ACTH stimu-
lation test when hydrocortisone is discontinued.
Discussion
A number of studies have suggested that the systemic
bioavailability and potential for adrenal suppression is
increased with FP compared to BUD. It is our suspicion
that his underlying adrenal suppression was revealed
presenting as withdrawal after switching to a less bioa-
vailable steroid. Adrenal suppression is an important
consideration for physicians tapering patients from
chronic high dose fluticasone therapy to less bioavailable
inhaled corticosteroids.
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